{"id":38555,"date":"2020-07-22T07:28:11","date_gmt":"2020-07-22T07:28:11","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=38555"},"modified":"2020-07-24T21:05:17","modified_gmt":"2020-07-24T21:05:17","slug":"literature-review-on-covid-19-in-people-with-immune-suppression","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/38555","title":{"rendered":"Review of COVID-19 in people with immune suppression"},"content":{"rendered":"

<\/b>Simon Collins, HIV i-Base<\/span><\/strong><\/p>\n

A recent review in CID looks at the increasing literature on COVID-19 in a range of different health conditions associated with immune suppression. <\/span><\/strong><\/p>\n

These populations includes cancer, hematologic malignancy, solid organ transplant, patients taking biologics and targeted disease modifying anti-rheumatic drugs, primary immunodeficiency, and HIV infection. <\/span><\/p>\n

The review concludes that with malignancy and solid organ transplant recipients, there might \u00a0be at increased risk of severe COVID-19 disease and including higher mortality.<\/span><\/p>\n

Evidence for other types of immunosuppression is less clear however, with further research, ideally prospective studies to determine the attributable risk of immunocompromising conditions and therapies on COVID-19 disease prognosis.<\/span><\/p>\n

comment<\/b><\/h3>\n

This paper was mainly included to highlight the impact of COVID-19 on related health conditions. The HIV review is useful, but HTB has reported on additional recent HIV coinfection studies. [2, 3]<\/b><\/p>\n

Reference<\/span><\/p>\n

    \n
  1. Fung M et al. COVID-19 in immunocompromised hosts: what we know so far. <\/span>Clinical Infectious Diseases, ciaa863. DOI: 10.1093\/cid\/ciaa863. (27 June 2020).
    \nhttps:\/\/academic.oup.com\/cid\/article\/doi\/10.1093\/cid\/ciaa863\/5864040<\/a><\/li>\n
  2. Latest studies on HIV\/COVID-19 coinfection. HTB 8(5). (26 June 2020).
    \n    https:\/\/i-base.info\/htb\/38257<\/a><\/li>\n
  3. Collins S. HIV and COVID-19 coinfection: case reports, retrospective cohorts and outcomes. HTB, HIV\/COVID-19 supplement (4). (1 June 2020).
    \n    https:\/\/i-base.info\/htb\/38000<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Simon Collins, HIV i-Base A recent review in CID looks at the increasing literature on COVID-19 in a range of different health conditions associated with immune suppression. These populations includes cancer, hematologic malignancy, solid organ transplant, patients taking biologics and …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[282,278],"tags":[],"class_list":["post-38555","post","type-post","status-publish","format-standard","hentry","category-covid-19-hiv-and-covid-19-coinfection","category-covid-19"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/38555","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=38555"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/38555\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=38555"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=38555"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=38555"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}